261 results about "Targeted release" patented technology

A method for delivering molecules to a central nervous system (CNS) of a subject includes supplying the molecules to a blood circulation of the CNS; supplying, to a body of the subject, a carrier system that encapsulates a nitric oxide (NO) facilitator; and applying energy to the carrier system at an energy level sufficient to cause the carrier system to release the NO facilitator in a blood circulation of the subject in a vicinity of a blood-brain barrier (BBB) of the subject and thereby increase passage of the molecules from the blood circulation of the CNS, through the BBB, and into the CNS of the subject.

A self-emulsifying drug delivery system to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and/or mixed glycerides and/or free fatty acids containing medium and/or long chain saturated, mono-unsaturated, and/or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron delivery and optimal bioavailability to a mammalian intestinal lumen. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic/non-amphiphilic solutes to induce semi-solid formation for targeted release rates.

Self-emulsifying drug delivery systems are provided to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and/or mixed glycerides and/or free fatty acids containing medium and/or long chain saturated, mono-unsaturated, and/or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron/lipoprotein delivery and optimal bioavailability through the mammalian intestinal tract. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic/non-amphiphilic solutes to induce semi-solid formation for targeted release rates.

A device for delivering an apparatus or object to a targeted location within a human subject is disclosed. The device includes a body, a handle mounted to and movable relative to the body, a tube, a cable, and retention unit. The tube has a first end fixed to the body and a second end fixed to the retention unit. The cable has a first end fixed to the handle and a second end remote from the body. The cable extends substantially through the tube. The retention unit applies a retention force sufficient to retain the capsule during endoscopic delivery to the targeted release location. Manipulation of the handle in a direction relative to the retention unit generates a force on the apparatus greater than the retention force. A method of use is also disclosed.

Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.

A modified release dosage product (5) comprises a plurality of minicapsules or minispheres (1, 2) containing nimodipine, and a plurality of minicapsules or minispheres (3), (4) containing tacrolimus. There are uncoated minicapsules or minispheres (1) encapsulating micronized nimodipine for immediate release and a controlled release polymer coated minicapsule or minisphere (2) encapsulating micronized nimodipine for delayed, sustained, controlled or targeted release. There are uncoated seamless minicapsules (3), the core of which comprises tacrolimus lipid-based formulation for immediate release and a controlled release polymer coated seamless minicapsule (4), the core of which comprises tacrolimus lipid-based formulation for delayed, sustained, controlled release or targeted release. The final dosage form may be a hard gelatin capsule (5).

Polyamine-co-ester-co-ortho ester) polymers, methods of forming active agent-load nanoparticles therefrom, and methods of using the nanoparticles for drug delivery are disclosed. The nanoparticles can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticles are less toxic, more efficient at drug delivery, or a combination thereof compared to a control or other transfection reagents.

The invention relates to poly-N- isopropyl acrylamide-poly-amino acid two section copolymer and the manufacturing method. It is made from poly-N-isopropyl acrylamide that the equal molecular weight is 1000-10000. The poly-amino acid is poly-L-glutamic acid or poly-L- aspartic acid that the equal molecular weight is 1000-30000. The copolymer has double responsibility to temperature and pH in water solution. The pH responding range would alter around the content of benzyl group in poly-amino acid. And it could take biodegradation. The invention could be used as carrier that the in vivo target released to medicine and could be used as injectable intelligent responding hydrogel.

The invention belongs to the technical field of high molecular materials, and in particular relates to preparation of a degradable environmental sensitive polymer nano hydrogel and an application. According to the invention, the degradable multiple environmental sensitive polymer nano hydrogel is obtained through precipitation polymerization by taking N-vinyl caprolactam as a main monomer, N, N'-di(acrylyl) cystamine as a crosslinking agent as well as hydrophilic monomers such as methylacrylic acid, hydroxymethyl acrylamide, polyethylene glycol monomethyl ether metacrylic acid ester (Mw=2000) as comonomers. According to the invention, the raw materials are easily-available, and the preparation method is simple. According to the method, water is used as the solvent, so that the method is environment-friendly. The polymer nano hydrogel prepared is good in dispersibility, uniform in size, and good in stability and biocompatibility. The phase inversion temperature of the polymer can be adjusted by controlling the use levels of methylacrylic acid, N-hydroxymethyl acrylamide and polyethylene glycol monomethyl ether metacrylic acid ester and the pH value of the environment. Therefore, the hydrogel can be applied to release of medicines in fixed points and is used as a carrier for targeted release of medicines.

The invention discloses a terminal amidocyanogen star-shaped lactic and glycolic acid/polyethyleneglycol segmented copolymer, a preparation method, drug-loaded nano-micelle and application thereof. The preparation method of the terminal amidocyanogen star-shaped lactic and glycolic acid/polyethyleneglycol segmented copolymer: (1) glycolide, polyhydroxy activator, stannous octoate and lactide are added into a polymerized tube sealing for vacuumized nitrogen permutation and reaction, and terminal hydroxyl star-shaped lactic and glycolic acid can be obtained; (2) butanedioic anhydride is added for reaction to prepare terminal carboxyl group star-shapedl actic and glycolic acid; (3) the terminal carboxyl group star-shaped lactic and glycolic acid is dissolved in anhydrous toluene, then doublepointed amidocyanogen polyethyleneglycol, N and N'- dicyclohexylcarbodiimide are added for reaction, solvent is evaporated to dryness and aether is added for sedimentation to prepare the terminal amidocyanogen star-shaped lactic and glycolic acid/polyethyleneglycol segmented copolymer which can form about 100nm of micelle automatically in water solution. Hydrophobic nature drugs can be loaded in the caryon of the micelle and putamen surface of the micelle is rich of high activity and freedom terminal amidocyanogen arms that can couple with various bioactivators to achieve the effect of targeted release.

The invention relates to preparation of sulfonated calix [4] arene-based nano supramolecular vesicles. According to the construction unit, sulfonated calix [4] arene is used as a subject (C4AS), asymmetrical purpurine is used as an object (MVC12), and a supramolecular assembly is constructed by including and coordinating interaction of the subject and the object. The preparation method comprises the following steps of: dissolving the C4AS and the MVC12 into water, and uniformly mixing the C4AS and the MVC12. The invention has the advantages that: the preparation method is simple and convenient; the consumption of raw materials of the subject and the object is low, and the subject and the object have high medicament load rate; the supramolecular vesicles have good response to the stimulus of external temperature, oxidation and reduction, addition of cyclodextrin and the like in short time; the supramolecular vesicles can load hydrophilic anti-cancer adriamycin; compared with pure adriamycin, the killing effect of the loaded adriamycin on cancer cells is not changed, and the toxic effect of the loaded adriamycin on normal cells is obviously reduced; and the supramolecular vesicles have broad application prospect in the fields of load, transport and targeted release of anti-cancer medicaments.

The invention relates to a compound nano drug carrier system with tumor promotion target capability and a preparation method of the system. The preparation method comprises the steps of connecting a 2,4,6-trimethoxybenzene ring to the surface of a mesoporous silicon nanoparticle through an epoxy ester bond, adopting beta-cyclodextrin as a 'valve' material, capping the surface of the mesoporous silicon nanoparticle with the beta-cyclodextrin by a subject-object effect of the cyclodextrin and the benzene ring, and grafting benzaldehyde terminated PEG (polyethylene glycol) to the surface of the beta-cyclodextrin through a pH (potential of hydrogen) sensitive imine bond to construct the compound nano drug carrier system capable of performing targeted release of a drug in a tumor cell. The constructed PEG/beta-CD/MSN (polyethylene glycol/beta-cyclodextrin/mesoporous silicon nanoparticle) compound nano drug carrier system is high in drug loading capacity, has double pH sensitivity mechanismsand more efficient targeted administration capability in the cancer cell, and can effectively increase a utilization ratio of the drug, reduce toxic and side effects of the drug, and better achieve targeted controlled release treatment of a cancer.

The invention discloses a core-shell structure cellulose-based probiotic microcapsule which is prepared by preparing a core from a mixture of a cellulose nanofiber and probiotics under the crosslinking action of Ca<2+>, preparing a coating from water-soluble chitosan and sodium alginate and by implementing a layer-by-layer self-assembling technique. The microcapsule disclosed by the invention hasan average particle size of 2-5mm, and is of a remarkable core-shell structure, probiotics are mainly distributed in the core of the microcapsule, amount controllable loading of the probiotics is achieved, good pH response properties and probiotic slow-release properties can be achieved, and effective protection on the probiotic and target release in intestinal tracts are achieved.

The present invention discloses a photodegradable crosslinking agent and a preparation method and applications thereof. A variety of photodegradable materials can be prepared by polymerizing the photodegradable crosslinking agent with other monomers. The prepared materials have photoresponsive properties, in the light stimulus, the materials may be subjected to response changes. The photodegradable crosslinking agent of the invention can solve problems existing in the prior field; a class of near-visible light and two-photon responsive organic photodegradable crosslinking agents are provided, can be used to prepare photoresponsive smart materials such as environmental friendly materials used in life, tissue engineering materials with an adjustable degradation rate, and drug delivery materials for targeted release. The photodegradable crosslinking agents are compounds having a structural formula shown in the specification.

The invention relates to a preparation method for a POSS/PDMAEMA organic/inorganic hybrid material according to a thiol-ene click chemistry method. The preparation method comprises the following steps: obtaining PDMAEMA through synthesis according to an RAFT polymerization method; taking dimethyl phenylphosphine as a catalyst, taking n-hexylamine as a reducer, and conducting a reduction reaction on a dithioester group at the tail end of PDMAEMA to generate sulfydryl; conducting thiol-Michael addition reactions on the double bonds of PDMAEMA containing sulfydryl and POSS containing ethenyl according to the thiol-ene click chemistry method to generate a POSS/PDMAEMA organic/inorganic hybrid material with a temperature/pH dual response. The preparation method has the advantages that the prepared POSS/PDMAEMA organic/inorganic hybrid material is small in size, stable in chemical bond, and uniform in particle diameter; due to a click reaction to PDMAEMA, the hydrophilic performance of POSS is effectively improved; in a water solution, the POSS/PDMAEMA organic/inorganic hybrid material is excellent in temperature sensibility and pH sensibility; due to a special structure and the stimulus response performance, the POSS/PDMAEMA organic/inorganic hybrid material is a new-generation environment-friendly new material product, and can be applied to drug carrying, targeted release, metal ion recovery, environmental pollutant adsorption and other fields.

The invention discloses a functionable superparamagnetic nano particle with uniform particle size. The nano particle is provided with a superparamagnetic nano particle core, and the magnetic nano particle core is connected with a plurality of water-soluble polymer chain segments and organic chain segments containing modifiable amino terminal groups respectively; and the magnetic nano-particle core is an MFe2O4 superparamagnetic nano particle, wherein metal M is one of Fe, Co and Mn, namely the magnetic nano particle is one of Fe3O4, CoFe2O4 or MnFe2O4, the particle size of the magnetic nano particle is between 4 and 12nm, and the particle size distribution is not more than 20 percent. The synthesized material can be widely applied to targeted release of medicaments, magnetic fluid hyperthermia, biofluorescent detection and the like. The synthesized magnetic nano-particle has uniform particle size, which ensures that the nano-particle meets the demand of biological application. At the same time, the surface of the nano-particle is modified with an organosilicon compound with an amino group remained at a terminal, and the amino group can be widely combined with bio-functional substances, thereby ensuring that the synthesized magnetic nano-particle can conveniently perform the bio-functionalization.

The invention discloses a hydrogel based on aptamer linking and a preparation method and application thereof. The hydrogel can connect different aptamers to realize the active targeting drug release to different cancer cells. The preparation method comprises the following steps: (1) connecting DNA single strand and acrylamide to obtain polymer chains, PS-A and PS-B; and (2) mixing the obtained PS-A, PS-B, an aptamer chain and an anticancer drug to obtain a drug loaded hydrogel. The hydrogel during preparation is directly mixed anticancer drugs, realizes drug entrapment during a self-assembly process. The hydrogel completes drug entrapment in the self-assembly process, is capable of specific recognition of cancer cells, achieves the targeting release of anticancer drug, and is suitable for targeted cancer therapy.

The invention discloses a method for predicting an optimal release point of an airdropped material. The method comprises: performing calculation by regarding a parachute as a three-dimensional 6-degree-of-freedom variable mass body, analyzing a motion characteristic of the airdropped material in a parachute opening and stable descent process according to an actual parachute descent working procedure, establishing a reliable dynamic model of a goods and materials airdropping process, simulating a motion track of the airdropped material after leaving from an aircraft, and calculating a parachute descent trajectory; and calculating and analyzing optimal release point, release time and release angle of the airdropped material with a Monte Carlo method according to a known target release point. With the method, the parachute descent airdropping process is subjected to high-precision dynamic modeling and solving, so that an airdropping point in a specified airdropping condition can be calculated reliably and a theoretical reference is provided for accurately mastering a release opportunity in a parachute descent implementation process to enable goods and materials to land in a predetermined landing site.

A spatial non-cooperative target autonomous relative navigation in-orbit validation system based on image information is disclosed. A target release mechanism receives an instruction from an on-boarddata bus to release a space-borne target, and the space-borne target has spatial non-cooperative target characteristics and enters the measurement range of a binocular camera; the binocular camera carries out stereoimaging and transmits sidereal time, satellite orbit, satellite attitude angle, binocular camera installation azimuth and pitch angle information to a data memory module; a data processing module carries out autonomous relative navigation calculation in real time, and calculated corresponding sidereal time and calculation results are sent to a ground data receiving system through adata transmission system; and the ground data receiving system stores the received data and carries out relative navigation calculation to obtain relative orbit and observation residual error of the non-cooperative target, and the calculation results are compared with the calculation results downloaded by the data transmission system so as to validate the on-board autonomous relative navigation.

The invention discloses a semi-interpenetrating network nano hybrid hydrogel and a preparation method and an application thereof. Firstly, chitosan is modified to prepare water soluble carboxymethyl chitosan (CMCS); then N-isopropylacrylamide (NIPAM), CMCS and (carboxyl functionalized) carbon nanotubes are subjected to in-situ free radical crosslinking polymerization reaction, and the semi-interpenetrating network nano hybrid hydrogel with different composition ratios of NIPAM, CMCS and the nanotubes is obtained. The prepared novel nano hybrid hydrogel has relatively high swelling rate, appropriate volume phase transition temperature and pH phase transition point, and high drug loading amount and continuous controllable drug release behavior. The hydrogel pharmaceutical preparation can be used as a promising hydrophilic oral drug carrier, is used for targeted release of oral vaccines, polypeptides, proteins and anticancer drugs, has low toxicity, and can be used for long-term treatment of colon cancer and the like.

A unique class of N-acyl O-amino phenol prodrugs of CBI-TMI and CBI-indole₂ were synthesized and shown to be prodrugs, subject to reductive activation by nucleophilic cleavage of a weak N—O bond, effectively releasing the free drug in functional cellular assays for cytotoxic activity approaching or matching the activity of the free drug, yet remain essentially stable to ex vivo DNA alkylation conditions. Most impressively, assessment of the in vivo antitumor activity of a representative O-(acylamino) prodrug, 8, indicate that they approach the potency and exceed the efficacy of the free drug itself (CBI-indole₂), indicating that the inactive prodrugs not only effectively release the free drug in vivo, but that they offer additional advantages related to a controlled or targeted release in vivo.

The invention discloses a method for preparing micro-particle-size W/O/W multiple emulsion carrying a medicine, which belongs to the technical field of medicinal preparations. The method comprises three steps: 1, dissolving the medicine to be carried and electrolyte for providing a osmotic pressure condition in a water phase together, emulsifying the water phase and an oil phase containing lipophilic emulsion stabilizer, and obtaining W/O initial emulsion; 2, mixing the initial emulsion and an external water phase containing a hydrophilic emulsion stabilizer, roughly dispersing and obtaining coarse multiple emulsion with a big particle size; and 3, diluting the coarse emulsion with deionized water, stirring gently, and obtaining the multiple emulsion product with a micro particle size. The principle of the preparation method is to promote emulsion drops of the coarse multiple emulsion to expand and break under a diluted condition by regulating the osmotic pressure of the internal water phase of the multiple emulsion so as to produce the multiple emulsion drops with a particle size of 1 to 10 micro meters. In the invention, the operation conditions are mild, the particle sizes of the multiple emulsion drops are small, the particle size range is narrow, the medicine entrapment rate is high, the stability of the preparation is high, the controlled-release and sustained-release effects on the carried medicine are good, and the lymph affine effect and targeted release effect of the emulsion are played more fully.

The invention belongs to the technical field of probiotics product preparation, and particularly relates to a preparation method of a room-temperature preserved bifidobacteria NQ-1501 enteric microcapsule. The preparation method comprises the following steps: firstly, performing top spray and granulation to bifidobacteria NQ-1501 bacterial powder by taking maltodextrin as an adhesive through a fluidized bed coating machine, and then coating a capsule core with starch and polypropylic acid resin, to prepare the room-temperature preserved bifidobacteria NQ-1501 enteric microcapsule with two coatings. Through the technological flow of firstly granulating the bifidobacteria NQ-1501 bacterial powder and then coating, the problems that the coating recovery rate is low and the surface coating of the microcapsule is uneven in thickness due to direct coating of lyophilized bacterial powder can be solved, and further the normal-temperature preservation and intestinal-targeted release functions of the bifidobacteria NQ-1501 microcapsule can be realized.